ArticleMetabolomics : Official journal of the Metabolomic Society2018
Metabolomic characterization of hypertension and dyslipidemia.
Article in Metabolomics : Official journal of the Metabolomic Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Highlights of three metabolites HDL and reduction in blood pressure values after dietary fiber supplementation in overweight and obese normotensive women: a metabolomic study.Metabolomics : Official journal of the Metabolomic Society · 2023Trial
- Association of plasma acylcarnitines and amino acids with hypertension: A nationwide metabolomics study.PloS one · 2023Trial
- Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies.International journal of hypertension · 2026Review
- Multi-Omics Elucidation of Edulinine's Intervention Mechanism in Hypertensive Rats.Current issues in molecular biology · 2025Article
- Effect of natural environmental changes on Hainan migratory population with hypertension in China and related plasma metabolism features.Scientific reports · 2025Article
- Nuclear Magnetic Resonance Analysis Seeking for Metabolic Markers of Hypertension in Human Serum.Molecules (Basel, Switzerland) · 2025Article
- A Scoring Model Using Multi-Metabolites Based on Untargeted Metabolomics for Assessing Dyslipidemia in Korean Individuals with Obesity.Metabolites · 2025Article
- Understanding Hypertension: A Metabolomic Perspective.Biology · 2025Review
- Higher Food and Lifestyle Oxidative Balance Scores Decreases the Risk of Hypertension in Chinese Adults: A Population-Based Cross-Sectional Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Elevated isoleucine may be a protective factor for primary hypertension: A pooled causal effect study.Medicine · 2025Article
- Metabolomics of the effects of Yishenjiangya granules in older adults with hypertension.Frontiers in pharmacology · 2025Article
- Systematic analysis of the burden of ischemic stroke attributable to high LDL-C from 1990 to 2021.Frontiers in neurology · 2025Article
- Association between human blood metabolome and risk of myocarditis: a mendelian randomization study.Scientific reports · 2024Article
- Metabolic Crosstalk in Multimorbidity: Identifying Compensatory Effects Among Diabetes, Hypertension, and Dyslipidemia.Journal of the Endocrine Society · 2024Article
- The effects of raspberry consumption on lipid profile and blood pressure in adults: A systematic review and meta-analysis.Food science & nutrition · 2024Review
- Plasma lipidomic profiling reveals six candidate biomarkers for the prediction of incident stroke in patients with hypertension.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Prevalence and associated factors of dyslipidemia in elderly people: Results from the Ardakan Cohort Study on Ageing, Iran.PloS one · 2024Article
- Genetic effects and causal association analyses of 14 common conditions/diseases in multimorbidity patterns.PloS one · 2024Article
- Developing a model to predict the early risk of hypertriglyceridemia based on inhibiting lipoprotein lipase (LPL): a translational study.Scientific reports · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHypertension and dyslipidemia are two main risk factors for cardiovascular diseases (CVD). Moreover, their coexistence predisposes individuals to a considerably increased risk of CVD. However, the regulatory mechanisms involved in hypertension and dyslipidemia as well as their interactions are incompletely understood.
objectivesThe aims of our study were to identify metabolic biomarkers and pathways for hypertension and dyslipidemia, and compare the metabolic patterns between hypertension and dyslipidemia.
methodsIn this study, we performed metabolomic investigations into hypertension and dyslipidemia based on a "healthy" UK population. Metabolomic data from the Husermet project were acquired by gas chromatography-mass spectrometry and ultra-performance liquid chromatography-mass spectrometry. Both univariate and multivariate statistical methods were used to facilitate biomarker selection and pathway analysis.
resultsSerum metabolic signatures between individuals with and without hypertension or dyslipidemia exhibited considerable differences. Using rigorous selection criteria, 26 and 46 metabolites were identified as potential biomarkers of hypertension and dyslipidemia respectively. These metabolites, mainly involved in fatty acid metabolism, glycerophospholipid metabolism, alanine, aspartate and glutamate metabolism, are implicated in insulin resistance, vascular remodeling, macrophage activation and oxidised LDL formation. Remarkably, hypertension and dyslipidemia exhibit both common and distinct metabolic patterns, revealing their independent and synergetic biological implications.
conclusionThis study identified valuable biomarkers and pathways for hypertension and dyslipidemia, and revealed common and different metabolic patterns between hypertension and dyslipidemia. The information provided in this study could shed new light on the pathologic mechanisms and offer potential intervention targets for hypertension and dyslipidemia as well as their related diseases.
Indexed as
Identifiers
30830367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.